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ABSTRACT12
The arylamine N-acetyltransferases (NATs) catalyze the acetylation of aromatic and heterocyclic 13
amines as well as hydrazines. All proteins in this family of enzymes utilize acetyl coenzyme A 14
(AcCoA) as an acetyl donor, which initially binds to the enzyme and transfers an acetyl group to 15
an active site cysteine. Here, we have investigated the role of a highly conserved amino acid 16
(Lys100) in the enzymatic activity of human NAT1. Mutation of Lys100 to either a glutamine or a 17
leucine significantly increased the Ka for AcCoA without changing the Kb for the acetyl 18
acceptor p-aminobenzoic acid. In addition, substrate inhibition was more marked with the mutant 19
enzymes. Steady state kinetic analyzes suggested that mutation of Lys100 to either leucine or 20
glutamine resulted in a less stable enzyme-cofactor complex, which was not seen with a 21
positively charged arginine at this position. When p-nitrophenylacetate was used as acetyl donor, 22
no differences were seen between the wild-type and mutant enzymes because p-23
nitrophenylacetate is too small to interact with Lys100 when bound to the active site. Using 3’-24
dephospho-AcCoA as the acetyl donor, kinetic data confirmed that Ly100 interacts with the 3’-25
phosphoanion to stabilise the enzyme-cofactor complex. Mutation of Lys100 decreases the 26
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affinity of AcCoA for the protein and increases the rate of CoA release. Crystal structures of 27
several other unrelated acetyltransferases show a lysine or arginine residue within 3 Å of the 3'-28
phosphoanion of AcCoA, suggesting that this mechanism for stabilizing the complex by the 29
formation of a salt bridge may be widely applicable in nature.30
31
Keywords: Arylamine N-acetyltransferase, kinetics, mutagenesis, AcetylCoenzyme A, lysine32
33
34
1. Introduction35
Acetyltransferases are a diverse superfamily of enzymes involved in the modification of 36
small drug molecules, xenobiotics, peptide and proteins. They are found in all prokaryotic and 37
eukaryotic species studied to date and are essential for numerous intracellular pathways. While 38
the acetyl acceptor varies considerably between different acetyltransferases, they all share a 39
common acetyl donor, acetylcoenzyme A (AcCoA). The arylamine N-acetyltransferases (NATs; 40
EC 2.3.1.5) are xenobiotic metabolizing enzymes widely distributed in the animal kingdom [1].41
They are distinguished by the presence of a conserved catalytic triad that prefers aromatic amine 42
and hydrazine substrates [2]. In humans, there are 2 NATs (NAT1 and NAT2) and their crystal 43
structure and catalytic function have been described in detail [3-6]. Both NAT1 and NAT2 are 44
genetically polymorphic, which im acts on the pharmacology of many therapeutic agents that 45
are metabolized by these enzymes [7]. Moreover, recent studies have shown a relationship 46
between NAT1 and cancer cell proliferation and survival suggesting that this protein is a 47
potential drug target [7, 8].  There have also been a number of reports on the development of 48
small molecule inhibitors for human and non-human NATs [9-12]. 49
The NATs catalyze the acetylation of small molecules via a double displacement or ping 50
pong bi bi reaction [13].  An in-depth understanding of the catalytic mechanism of the 51
mammalian NAT’s was provided by Wang et al who examined the acetylation of various 52
substrates by the hamster homolog of NAT1 using Bronsted plot analyses, kinetic solvent isotope 53
effects and pH-dependence studies [14, 15]. This work showed that the formation of a thiolate-54
imidazolium ion pair by Cys68 and His107 was essential for enzymatic function. The acetyl donor, 55
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which binds first, is orientated by several amino acids that line the cavity of the active site. This 56
is true for both mammalian and bacterial NAT [6, 16]. In human NAT2, the amino acids reside 57
in the 2 and 3 domains, which extent from amino acids 93-104 (FYIPPVNKYSTG), and in 58
the 9 domain at amino acids 208-217 (YLQTSPTSF). These regions are highly conserved 59
across mammalian NATs suggesting a common mechanism for AcCoA binding (Figure 1A). 60
The outer surface of the active site pocket for both human NAT1 and NAT2 contains a 61
conserved lysine (Lys100). The crystal structure of the NAT2-CoA binary complex shows that 62
Lys100 is in close proximity to the 3’-phosphoanion of CoA (RCSB Protein Data Bank 2PFR) [6].  63
A similar arrangement is seen with the -amino group of Lys248 in the NAT homolog from 64
Bacillus anthracis [16]. In the mammalian NATs, K100 is located on the flexible 2-3 loop, 65
which shifts towards the center of the active site cleft upon CoA binding [6].   This suggests that 66
Lys100 may be involved in the interaction of the acetyl donor with the NATs. 67
NAT1 is widely distributed in the body and is responsible for metabolism of many 68
therapeutic and carcinogenic compounds [17]. The crystal structure of NAT1 has been reported 69
and it retains the same structural features as other mammalian NATs [6]. Site-directed 70
mutagenesis has been extensively used with both NAT1 and NAT2 to discover critical amino 71
acids involved in the reaction mechanism [15, 18, 19], substrate specificity [20] and stability [21, 72
22]. Because recent studies have suggested that NAT1 may be a novel drug target [7, 8], insight 73
into how substrates interact with the protein provides important information for the design and 74
development of small molecule inhibitors. In the present study, we have investigated the role of75
the conserved K100 in the acetylation of substrates by NAT1 using steady state enzyme kinetics76
of wild-type and K100 mutants that vary in the charge of their side chain. In addition, different 77
acetyl donors have been studied with the view of establishing whether K100 influences their 78
interaction with the enzyme.79
80
2. Materials and Methods81
82
2.1. Materials.83
84
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p-Aminobenzoic acid, acetylcoenzyme a, de-phospho-coenzyme A and acetic anhydride were 85
obtained from Sigma Aldrich (St Louis, USA). RPMI1640, serum and LipofectAMINE 2000 86
were obtained from Life Technologies (Victoria, Australia). Primers were purchased from 87
GeneWorks (South Australia, Australia). All other chemicals were of analytical grade.88
89
2.2 Cells Culture. 90
91
HeLa cells were obtained from the American Type Culture Collection (Manassas, VA) 92
and cultured in RPMI-1640 medium supplemented with 5% fetal bovine serum at 37oC in a 93
humidified 5% CO2 atmosphere.94
95
2.3. Mutagenesis.96
97
Lys100 was mutated to either a glutamine, leucine or arginine residue using the 98
GENEART site-directed mutagenesis system (Life Technologies, Vic, Australia) as described in 99
the manufacturer’s protocol. Wild-type FLAG-tagged human NAT1 22 was used as template with 100
the following primers; K100Q FP, 5’-agcactccagccaaacaatacagcactggcatg-3’, K100Q RP, 5’-101
catgccagtgctgtattgtttggctggactgct-3’, K100L FP, 5’-agcactccagccaaattatacagcactggcatg-‘3, K100L 102
RP, 5’- catgccagtgctgtaaattttggctggactgct -3’, K100R FP, 5’-agcactccagccaaaagatacagcactggcatg-103
3’, K100R RP,5’- catgccagtgctgtatcttttggctggactgct -3’. Clones were verified by sequencing.104
105
2.4. Transient Transfection and Protein Expression. 106
107
Cells were seeded at a density of 0.8 × 106 cells/well in 6-well plates and allowed to 108
adhere overnight. They were then transiently transfected with 4 µg plasmid DNA using 109
LipofectAMINE 2000 according to the manufacturer’s instructions and incubated overnight. 110
Cells were washed twice with cold PBS and then scraped into 0.6 ml of 20 mM Tris/1 mM 111
EDTA buffer (pH 7.4) containing 1 mM dithiothreitol and disrupted on ice by sonication. Cell 112
lysates were centrifuged at 16,000 × g for 10 min (4oC) and the supernatants retained for FLAG 113
Western blot and NAT1 activity assays.114
115
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2.5. NAT1 Assay. 116
117
NAT1 activity was assayed using p-aminobenzoic acid (PABA) as substrate and either 118
AcCoA, dephospho-AcCoA, or p-nitrophenylacetate (pNPA) as cofactor. N-acetyl-PABA was 119
measured by high performance liquid chromatography as previously described. 23 Kinetic 120
parameters for PABA were determined using 1100 µM cofactor and 0 to 1200 µM PABA. For 121
the determination of cofactor kinetic parameters, 420 µM PABA was used with 0 to 1200 µM 122
cofactor. All reactions were performed under linear conditions with respect to substrate and 123
protein. NAT1 activities were normalized for protein expression using FLAG Western blots of 124
each cell lysate.125
126
2.6. Synthesis of Dephospho-AcCoA. 127
128
Acetyl-3’-dephospho-coenzyme A was synthesized s previously described. 22 Briefly, 129
2.3 mg 3’-dephospho-coenzyme A (Sigma-Aldrich) was dissolved in 200 l NH4OH. Acetic 130
anhydride (16 l) was added on ice over 30 min with shaking. The solution was then freeze dried 131
to remove the solvent and the excess acetic acid. The acetyl-3’-dephospho-coenzyme A was 132
dissolved in water and analyzed by HPLC before use.133
134
2.7. Data Analysis. 135
136
Steady state kinetics were analyzed based on the reaction mechanism shown in Scheme 1, 137
which describes a double displacement or ping pong bi bi reaction with substrate inhibition. The 138
initial velocity (v) was described by:139
                                                    (1)140
where Vmax = maximum velocity, A = acetyl donor concentration (AcCoA or pNPA), B = 141
acetyl acceptor concentration (PABA), Ka = kinetic constant for the acetyl donor, Kb = kinetic 142
constant for the acetyl acceptor (PABA) and Ki = substrate inhibition constant.  For experiments 143
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where the acetyl acceptor was varied and the acetyl donor was constant, equation 1 was 144
rearranged to:145
                                                     (2)146
All kinetic parameters were estimated by nonlinear least squares regression using GraphPad 147
Prism 6 (GraphPad Software, La Jolla, USA) and comparisons were performed using a Student’s 148
t-test. Convergence was confirmed by initiating the iterative process from at least 3 independent 149
initial estimates. Kinetic parameters were compared by one way analysis of variance.150
151
2.8. Crystal structure analysis. 152
153
All crystal structure coordinates were obtained from the Brookhaven protein database and 154
were visualized using Swiss PDB Viewer Ver 4.0.1 (Swiss Institute of Bioinformatics). Reported 155
distances were calculated using the same software.156
157
3. Results158
159
3.1. Steady state kinetics of PABA acetylation by NAT1.160
161
The mechanism for the acetylation of substrates by NAT1 is shown in Figure 2A and 162
comprises 2 sequential reactions. AcCoA initially binds to the enzyme and acetylates Cys68. 163
Following release of CoA, the acetyl acceptor interacts with the acetylated enzyme to form 164
product. The second reaction is independent of the acetyl donor as it leaves the enzyme before 165
the acetyl acceptor binds. However, as with many ping pong bi bi reactions, competition between 166
acetyl donor and acetyl acceptor for the unacetylated enzyme can occur. This results in substrate-167
dependent inhibition at high concentrations, as has been described for the human NATs [23].168
Initially, we examined the kinetics of NAT1 acetylation using the different acetyl donors, 169
AcCoA and pNPA.  Both compounds readily support the first half of the reaction but pNPA is 170
much smaller and lacks the phosphor-ADP and pantothenic groups of AcCoA that interact with 171
the 2 and 3 domains of the enzyme (Figure 2C). For pNPA, the reaction kinetics are slightly 172
different to that for AcCoA because pNPA reportedly does not form a Michaelis complex [14]. 173
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Equation 1 and 2 still described the relationship between concentrations and reaction velocities. 174
However, the interpretation of Ka is somewhat different. For AcCoA, Ka =[ k4*(k-1 +k2)]/[k1(k2 + 175
k4)] whereas for pNPA, Ka = k4/k2 [14].176
Initially, the kinetics of PABA acetylation was studied in wild-type enzyme ectopically 177
expressed in HeLa cells to ensure post-translational modification of the enzyme. The initial rates 178
of reaction using pNPA and AcCoA as acetyl donors are shown in Figure 3A. Substrate 179
inhibition was evident for both donors, although this was seen at a lower substrate concentration 180
with pNPA. To determine the kinetic parameters for both the acetyl donors and the acetyl 181
acceptor, equation 2 was simultaneously fitted to the data with the assumption that Kb and Ki are 182
independent of the acetyl donor used. The resulting kinetic parameters are shown in Table 1183
(rows 1 and 4).  For pNPA, Ka was almost 10 times that seen for AcCoA. In addition, Vmax was 184
almost 4 fold greater for pNPA. Vmax is a measure of the rate of product formation and, for a 185
double displacement mechanism, it is equal to the product of [S●AcE] and k4 (Figure 2A & B).186
Since k4 is independent of the acetyl donor, the difference in Vmax indicates that the steady state 187
[S●AcE] was higher for pNPA.  188
189
3.2. Effect of Lys100 mutations on NAT1 kinetics. 190
191
To examine the role of Lys100 in NAT1 catalytic activity, the amino acid was mutated to 192
either a glutamine (K100Q) or a leucine (K100L).  With pNPA as the acetyl donor, PABA 193
acetylation was similar for both the wild-type and the mutated forms of the enzyme (Figure 3B). 194
The estimated steady state kin tic parameters are shown in Table 1 (rows 1-3).  The lack of any 195
effect following mutation indicates that Lys100 is not involved in the binding of pNPA to the 196
enzyme, which is consistent with its location deep within the catalytic pocket away from the 2 197
and 3 domains. In addition, the results suggest Lys100 does not influence the binding of the 198
acetyl acceptor (PABA) to the enzyme. Using the kinetic parameter estimates in Table 1, 199
inhibition by PABA at the different concentrations was calculated and is plotted in Figure 3C. 200
The data show that mutation of Lys100 did not affect the competition between pNPA and PABA 201
for the unacetylated enzyme.  The lack of any change in the estimates for the PABA inhibition 202
constant Ki is in agreement with this conclusion.  203
Page 9 of 28
Ac
ce
pte
d M
an
us
cri
pt
8
When AcCoA was used as the acetyl donor, the reaction kinetics were very different 204
between the mutant and the wild-type enzymes (Figure 3D). Table 1 (rows 4-6) shows a 205
significant increase (p<0.05) in the acetyl donor kinetic constant (Ka) from 0.68 mM for the 206
wild-type enzyme to 8-10 mM for the K100Q and K100L mutant enzymes. Moreover, the extent of 207
substrate inhibition was much greater for the mutant enzymes (Figure 3E). This suggests that the 208
affinity of AcCoA for the enzyme was decreased since Ki did not change (Table 1).209
To test whether the charge at K100 affected NAT1 activity, the lysine was mutated to an 210
arginine (K100R) and the resulting steady state velocities are shown in Figure 3D. The Ka for 211
AcCoA was similar to that for the wild-type enzyme (Table 1). However, the K100R mutant did 212
not fully recover activity as the Vmax for the reaction was significantly less (p<0.05) than that of 213
the wild-type enzyme. Nevertheless, these results suggest that the charge of the amino acid at214
position 100 influences the affinity of AcCoA for the enzyme.215
To confirm the effects of K100 mutation on the kinetics of AcCoA, steady state reaction 216
velocities were determined using a constant PABA concentration (420 M) and increasing 217
AcCoA concentrations for both the wild-type and mutant enzymes (Figure 3F). Over the 218
concentration range of 0 to 1.2 mM, saturation of the wild-type and K100R enzymes was seen. 219
This is consistent with the Ka less than 1 mM shown in Table 1. By contrast, activity was 220
significantly less and no saturation was seen with the K100L and K100Q enzymes, in agreement 221
with the increased Ka for these enzymes. The parameter Vmax/Ka is the rate constant for the 222
association and formation of a productive complex (acetylated enzyme intermediate) by the 223
acetyl donor [24]. For pNPA, Vmax/Ka was independent of Lys
100 (Table 1). By contrast, for 224
AcCoA, Vmax/Ka decreased more than 4 fold when Lys
100 was replaced with either a glutamine or 225
a leucine. This indicates that the mutated enzymes do not form a productive complex with 226
AcCoA to the same degree as the wild-type enzyme.227
228
3.3. Effect of the 3’-phosphoanion of AcCoA on NAT1 kinetics.229
230
Because the crystal structure of CoA bound to NAT2 suggested that K100 might interact 231
with the 3’-phosphoanion of the acetyl donor, 3’-dephosphorylated AcCoA (dephospho-AcCoA) 232
was synthesized and used as the acetyl donor (Figure 2C). The steady state velocities are shown 233
in Figure4. For the wild-type and K100R enzymes, Ka was high (~15 mM), similar to that seen for 234
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AcCoA with the K100L and K100Q enzymes (Table 1). These data suggest that removal of the 235
positive charge at position 100 of NAT1 or removal of the negative 3’-phosphoanion from the 236
acetyl donor had the same effects on enzyme kinetics.  Surprisingly, the Ka for dephospho-237
AcCoA increased even further when the K100L and K100Q enzymes were examined (Table 1), 238
resulting in a further decrease in activity for PABA acetylation (Figure 4). Thus, removal of both 239
the positively charged amino acid at position 100 and the negatively charged 3’-phosphoanion on 240
AcCoA affected enzyme activity much greater than each of the individual changes.  This is 241
shown in the estimates for Vmax/Ka. For the wild-type enzyme, Vmax/Ka decreased from 2955 +242
345 for AcCoA as acetyl donor to 405 + 45 for dephospho-AcCoA as acetyl donor. Moreover, 243
this value decreased further to ~ 200 when Lys100 was replaced by either glutamine or leucine. 244
However, unlike that seen with AcCoA, there was no difference in activity between the wild-245
type enzyme and the K100R mutant when dephospho-AcCoA was used as the acetyl donor (Table 246
1 and Figure 4). 247
248
3.4. Lysine-CoA interactions in other arylamine N-acetyltransferases.249
250
We examined the structures of several other arylamine N-acetyltransferase-CoA 251
complexes available in public databanks to determine whether the binding of the 3’-252
phosphoanion of AcCoA to a lysine residue was common for this class of emzyme. Figure 5 253
shows structures for NAT from Bacillus anthracis (RCSB Protein Data Bank 3LNB), published 254
by Pluvinage et al ([16], and for NAT from Mycobacterium marinum (RCSB Protein Data Bank 255
2VFC), published by Fullam et al [25]. For B anthracis, Lys248 is located at the surface of the 256
catalytic pocket and within 3 Å of the 3’phosphoanion of CoA, sufficiently close to form a salt 257
bridge. The crystal structure indicates that Lys248 may also interact with the 5’-phosphate as well258
(Figure 5A). For M marinum, the lysine closest to the 3’-phosphoanion of CoA is Lys236, which 259
is within 3.3 Å of the -amino group. However, the crystal structure suggests that Lys236 does not 260
interact with the 5’phosphoanion. If this were the case, then it could be predicted that the 261
enzyme-AcCoA complex is more stable for B anthracis because of the dual interaction of the 262
acetyl donor with Lys248. This should result in a lower Ka for the acetylation reaction. Indeed, 263
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this is the case. Pluvinage et al reported an AcCoA Kmapp of 50M for the B anthracis enzyme 264
and approximately 200 M for the M marinum enzyme.265
266
4. Discussion267
The arylamine N-acetyltransferases are a family of ancient enzymes found across many 268
prokaryotes and eukaryotes species [1]. They have been associated with a number of human 269
disorders including drug resistance [26, 27], drug hypersensitivity [28, 29], atopic allergic 270
responses [30], and drug-induced liver disease [31]. More recently, the NATs have been 271
proposed as possible small molecule drug targets [7, 8, 32] and an understanding of their 272
structure and catalytic mechanism may provide important leads to designing such targets.  In the 273
present study, we have investigated the role of a conserved lysine residue located at the surface 274
of the catalytic pocket of NAT1, and found that this amino acid is important in AcCoA binding 275
to the enzyme. These results suggest that the design of NAT1 inhibitors could include binding to 276
K100. This may increase affinity because K100 appears to significantly stabilize the substrate-277
enzyme complex even when other amino acids in the active site pocket are involved in binding. 278
Experiments replacing AcCoA with the acetyl donor pNPA support a role for Lys100 in 279
the interaction of AcCoA with NAT1. pNPA is much smaller than AcCoA and is unlikely to 280
make contact with Lys100 when located in the active site of the enzyme. There were no major 281
differences in the steady-state kinetics of PABA acetylation between the wild-type and mutant 282
proteins when pNPA was used as the acetyl donor. These kinetic data and previously published 283
co-crystal structures of NATs-CoA [6] indicate that Lys100 interacts with the 3’-phosphoanion of 284
AcCoA, and this finding was supported by experiments using dephospho-AcCoA.285
Analysis of the kinetic constants provides some insight into how Lys100 affects 286
AcCoA binding.  The lack of any effect of Lys100 mutation on enzyme activity with pNPA as 287
acetyl donor indicates that this amino acid does not influence PABA binding to the enzyme or 288
the rate of product release, that is, k3, k-3 or k4 (Figure 2A). When Lys
100 was mutated to either a 289
glutamine or a leucine, Vmax more than doubled (Table 1). Vmax is proportional to k2.k4/(k2+k4) 290
[14] and since k4 was unaffected, Lys
100 must primarily influence k2, the rate constant for the 291
release of CoA from the enzyme. An increase in k2 will also lead to an increase in the steady 292
state concentration of the intermediates Ac-E, which would increase the rate of acetyl acceptor 293
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binding to the intermediate (Figure 2A).  However, the data do not exclude the possibility that 294
Lys100 is also involved in the association and/or dissociation of AcCoA (that is, k1 and k-1). 295
Figure 3E indicates that PABA competes more effectively with AcCoA for the K100Q and K100L 296
proteins compared to the wild-type enzyme. Since the binding of PABA to the enzyme was not 297
influenced by either of these mutations, the data indicate that the affinity of AcCoA for NAT1 298
decreased when the charge at position 100 was changed to a non-positive amino acid. The 299
overall outcome of modifying Lys100 is a less efficient first half of the reaction (due to a deceased 300
rate of productive interaction between the enzyme and AcCoA) and a more efficient second half 301
of the reaction (due to a faster release of CoA and a higher steady state concentration of the Ac-E 302
intermediate). This conclusion was supported by the experiment in Figure 3E where AcCoA 303
concentration was varied, which showed an increase in Ka. For AcCoA, Ka is a function of k1, k-304
1, k2 and k4 (see above and [14]). Since k4 was unaffected by mutation of K
100, the increase in Ka305
suggests a change in k1, k-1 or k2. Each of these parameters are involved in AcCoA binding 306
and/or the initial acetylation of the active site cysteine.307
308
Removal of the 3’-phosphoanion from AcCoA produced the expected changes in PABA 309
kinetics that mimicked removal of the positive charge at Lys100. However, somewhat 310
unexpectedly, the steady state kinetics for PABA acetylation by the K100Q and K100L mutants 311
showed an even larger increase in Ka to ~ 28 mM. The reason for this is currently unknown but 312
suggests that Lys100 may interact with AcCoA in addition to the 3’-phosphoanion. The crystal 313
structure of NAT from B anthracis suggests Lys248 can simultaneously interact with the 3’-314
phosphoanion and the 5’-phosphoanion of CoA (Figure 5A), but this is unknown for NAT1.315
The interaction of quaternary amines with phosphates has been shown to be a highly 316
stable non-covalent bond [33] so their presence in proteins complexed with small molecule 317
phosphates is expected. The crystal structures of several acetyltransferases unrelated to the NATs 318
also show lysine interactions with CoA. For human choline acetyltransferase, two lysines 319
stabilize the enzyme-CoA complex [34]. Lys407 engages with the 3’-phosphoanion while Lys403320
interacts with the 5’-phosphoanion. Similarly, Lys192 in dopamine acetyltransferase from D. 321
melanogaster reportedly forms a salt bridge with the 3’-phosphoanion of CoA [35]. There are 322
several other AcCoA-dependent enzymes including GNAT [36], tubulin acetyltransferase [37]323
and carnitine acetyltransferase[38] where a protein-CoA co-crystal shows the -amino group of a 324
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lysine located at a distance from the 3’-phosphoanion that would support the formation of a salt 325
bridge (Figure 6). By contrast, there are several acetyltransferases where the guanidine side chain 326
of an arginine is positioned within 3 Å of the 3’-phosphoanion of bound CoA. These include 327
spermine-spermidine acetyltransferase (Arg142 and Arg143) [39] and serotonin acetyltransferases 328
(Arg170) [40]. Both arginine and lysine residues readily undergo post-translational modification, 329
including methylation, acetylation sumoylation and ubiquitination, which would be a novel 330
mechanism for regulating acetyltransferase activity by altering AcCoA binding. However, there 331
currently is scant evidence for post-translational modification of the NATs. An exception is a 332
recent study by Zhang et al, who demonstrated acetylation of 2 lysine residues in NhoA, a N-333
hydroxyarylamine O-acetyltransferase from E. coli [41]. However, it is unknown if either of 334
these lysines interact with AcCoA. We are currently investigating whether Lys100 in NAT1335
undergoes modification and, if so, whether these changes affect enzyme function.336
337
338
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493
Table 1. 494
Kinetic parameters for p-aminobenzoic acid acetylation by NAT1495
Enzyme Acetyl
Donor
Vmax
a Ka
(mM)
Kb
(mM)
Ki
(mM)
Vmax/Ka
WT pNPA 7540 ± 410 5.81 ± 0.61 0.21 ± 0.01 1.34 ± 0.09 1300 ± 155
K100Q pNPA 7065 ± 225 6.05 ± 0.21 0.20 ± 0.06 1.65 ± 0.10 1170 ± 55
K100L pNPA 6075 ± 330* 5.27 ± 0.34 0.18 ± 0.12 1.52 ± 0.19 1150 ± 95
WT AcCoA 2010 ± 109 0.68 ± 0.07 0.21 ± 0.01 1.34 ± 0.09 2955 ± 345
K100Q AcCoA 5910 ± 370** 10.60 ± 0.75** 0.19 ± 0.15 1.48 ± 0.14 560 ± 55**
K100L AcCoA 4840 ± 230** 8.28 ± 0.46** 0.18 ± 0.10 1.54 ± 0.13 585 ± 40**
K100R AcCoA 760 ± 30** 0.67 ± 0.04 0.20 ± 0.10 1.45 ± 0.38 1135 ± 80
WT d-AcCoA 6145 ± 460 15.2 ± 1.3 0.19 ± 0.02 1.42 ± 0.08 405 ± 45
K100Q d-AcCoA 5885 ± 260 28.8 ±1.4** 0.21 ± 0.02 0.91 ± 0.14 205 ± 15*
K100L d-AcCoA 4860 ± 140 28.1 ± 0.8** 0.13 ± 0.05 1.10 ± 0.11 175 ± 7*
K100R d-AcCoA 6050 ± 250 12.9 ± 0.6 0.27 ± 0.04 1.67 ± 0.31 470 ± 25
496
anmol/min/DU where DU = density units from Western blots.
* p<0.05; ** p<0.01 compared to respective control (WT) using one-way analysis of variance with 
Tukey’s correction for multiple comparisons.
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Figure legends
Figure1. Sequence homology of mammalian NATs in the β2-β3 and α9 region of the protein. Blue 
underlined letters refer to amino acids identified in the human NAT2 crystal structure that bind specific 
regions of the AcCoA molecule [6]. The conserved lysine at position 100 is shown in red.
Figure 2. Acetylation of substrate by human NAT1. The double displacement or ping pong bi bi 
mechanism for the NATs shows acetylation of the active site cysteine by AcCoA followed by the 
transfer of the acetyl group to the primary amine of the substrate.( A) Reaction mechanism for AcCoA 
as the acetyl donor, where a Michaelis complex is formed. (B) Reaction mechanism of pNPA as the 
acetyl donor, where no Michaelis complex is formed [14]. For both reactions, the reversible binding of 
substrate to the unacetylated enzyme results in substrate inhibition. (C) Structure of the different acetyl 
donors used in the current study.
Figure 3. Acetylation of PABA by human NAT1. (A) Kinetic curves for wild-type (WT) NAT1 activity 
with a constant acetyl donor concentration (1100 M) and increasing acetyl acceptor concentration. (B) 
Acetylation of PABA by WT, K100L and K100Q NAT1 mutations with pNPA (1100 M) as the acetyl 
donor. (C) Calculated substrate inhibition from the data in B at each concentration of PABA. (D) 
Acetylation of PABA by WT, K100L, K100Q and K100R NAT1 mutations with AcCoA (1100 M ) as the 
acetyl donor. (E) Calculated substrate inhibition from the data in D at each concentration of PABA. (F)
Acetylation of PABA by WT, K100L, K100Q and K100R NAT1 mutations at a constant PABA 
concentration (420 M) and increasing AcCoA concentrations. All data are mean ± s.e.m, n = 3. DU = 
density units obtained from quantification of Western blots.
Figure 4. Acetylation of PABA by WT,  K100L, K100Q and K100R NAT1 mutations at a constant 
concentration (1100 M) of dephospho-AcCoA as acetyl donor. Data are shown as mean ± s.e.m, n = 3. 
DU = density units obtained from quantification of Western blots.
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Figure 5. Location of lysine residues in bacterial NATs bound with AcCoA. (A) Crystal structure of 
Bacillus anthracis NAT showing the location of Lys248 in relation to the 3’-phosphoanion and 5’-
phosphoanion groups of AcCoA. Structural coordinates were taken from Brookhaven database (3LNB) 
after the work of Pluvinage et al ([16]. (B) Crystal structure of Mycobacterium marinum NAT showing 
the location of Lys236 in relation to the 3’-phosphoanion of AcCoA. Structural coordinates were obtained 
from Brookhaven database (2VFC) after the work of Fullam et al [25]. Structures were drawn with 
Swiss PDB Viewer (4.1), which was also used to calculate distances.
Figure 6.  Structural analysis of AcCoA binding to acetyltransferases. Structures showing lysine 
residues in close proximity to the 3’-phosphoanion of AcCoA. Structural coordinates were obtained 
from Brookhaven database. Choline acetyltransferase = 2FY5; dopamine acetyltransferase = 3T4E; 
GNAT = 2I79; tubulin acetyltransferase = 4H6Z; polyamine acetyltransferase = 3QB8; carnitine 
acetyltransferase = 1NDB. Structures were drawn with Swiss PDB Viewer (4.1), which was also used to 
calculate distances.
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